More recently, genome-wide association studies (GWAS) have identified ABCA1 polymorphisms as strongly linked to a high risk of developing AD [14], thus reinforcing the hypothesis that the LXR/ABCA1 axis could be a promising drug target for AD. This evidence concerns the gene ABCA1 and Alzheimer disease.